THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE

Show other versions (1)

The clinical significance  of CYP2C19 genetic polymorphism, associated with the violation of the formation of the active clopidogrel metabolite, for efficacy and safety of this drug in cardiology practice is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 test...

Full description

Bibliographic Details
Main Authors: K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2015-09-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
резистентность к клопидогрелу
фармакогенетика
CYP2С19
Online Access:http://www.rpcardio.ru/jour/article/view/99

Similar Items

Similar Items